A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer

Polly Niravath, Yee Lu Tham, Tao Wang, Angel Rodriguez, Claudette Foreman, Susan G. Hilsenbeck, Richard M Elledge, Mothaffar Rimawi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background. Brain metastasis from breast cancer presents a significant threat to women’s health and quality of life. Capecitabine and sunitinib have shown some activity in this setting; there- fore, we conducted a single-arm phase II trial with these agents. Methods. Patients with breast cancer and central nervous system (CNS) metastases received whole-brain radiotherapy concurrently with capecitabine (1,000 mg/m2 per day for 14 consecutive days), followed by concomitant capecitabine (2,000 mg/m2 per day for 2 weeks followed by a 1-week break) and sunitinib (37.5 mg daily, continuously). The primary end- point was progression-free survival (PFS).Results. Of 25 planned patientsthat would be required to detect a 4-month improvement (from 5 to 9 months) in median PFS with 80% power, 12 were enrolled, and the study was then closed forslow accrual. Median PFS was 4.7 months, and median overall survival was 10 months. In the CNS, 25% had progressive disease, and 83% experienced extra-CNS progression. The most common side effects were fatigue and nausea.Conclusion. In 12 evaluable patients studied, concurrent capecitabine and whole-brain radiation followed by capecita- bine and sunitinib did not extend PFS over historical rates and was associated with significant toxicity. Our study was small and closed due to slow accrual.

Original languageEnglish (US)
Pages (from-to)13
Number of pages1
JournalOncologist
Volume20
Issue number1
DOIs
StatePublished - 2015

Fingerprint

Radiotherapy
Disease-Free Survival
Breast Neoplasms
Neoplasm Metastasis
Brain
Central Nervous System
Women's Health
Nausea
Fatigue
Quality of Life
Capecitabine
sunitinib
Radiation
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer. / Niravath, Polly; Tham, Yee Lu; Wang, Tao; Rodriguez, Angel; Foreman, Claudette; Hilsenbeck, Susan G.; Elledge, Richard M; Rimawi, Mothaffar.

In: Oncologist, Vol. 20, No. 1, 2015, p. 13.

Research output: Contribution to journalArticle

Niravath, Polly ; Tham, Yee Lu ; Wang, Tao ; Rodriguez, Angel ; Foreman, Claudette ; Hilsenbeck, Susan G. ; Elledge, Richard M ; Rimawi, Mothaffar. / A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer. In: Oncologist. 2015 ; Vol. 20, No. 1. pp. 13.
@article{3df4d0f03d2f496d868e70f1b791bed7,
title = "A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer",
abstract = "Background. Brain metastasis from breast cancer presents a significant threat to women’s health and quality of life. Capecitabine and sunitinib have shown some activity in this setting; there- fore, we conducted a single-arm phase II trial with these agents. Methods. Patients with breast cancer and central nervous system (CNS) metastases received whole-brain radiotherapy concurrently with capecitabine (1,000 mg/m2 per day for 14 consecutive days), followed by concomitant capecitabine (2,000 mg/m2 per day for 2 weeks followed by a 1-week break) and sunitinib (37.5 mg daily, continuously). The primary end- point was progression-free survival (PFS).Results. Of 25 planned patientsthat would be required to detect a 4-month improvement (from 5 to 9 months) in median PFS with 80{\%} power, 12 were enrolled, and the study was then closed forslow accrual. Median PFS was 4.7 months, and median overall survival was 10 months. In the CNS, 25{\%} had progressive disease, and 83{\%} experienced extra-CNS progression. The most common side effects were fatigue and nausea.Conclusion. In 12 evaluable patients studied, concurrent capecitabine and whole-brain radiation followed by capecita- bine and sunitinib did not extend PFS over historical rates and was associated with significant toxicity. Our study was small and closed due to slow accrual.",
author = "Polly Niravath and Tham, {Yee Lu} and Tao Wang and Angel Rodriguez and Claudette Foreman and Hilsenbeck, {Susan G.} and Elledge, {Richard M} and Mothaffar Rimawi",
year = "2015",
doi = "10.1634/theoncologist.2014-0278",
language = "English (US)",
volume = "20",
pages = "13",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "1",

}

TY - JOUR

T1 - A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer

AU - Niravath, Polly

AU - Tham, Yee Lu

AU - Wang, Tao

AU - Rodriguez, Angel

AU - Foreman, Claudette

AU - Hilsenbeck, Susan G.

AU - Elledge, Richard M

AU - Rimawi, Mothaffar

PY - 2015

Y1 - 2015

N2 - Background. Brain metastasis from breast cancer presents a significant threat to women’s health and quality of life. Capecitabine and sunitinib have shown some activity in this setting; there- fore, we conducted a single-arm phase II trial with these agents. Methods. Patients with breast cancer and central nervous system (CNS) metastases received whole-brain radiotherapy concurrently with capecitabine (1,000 mg/m2 per day for 14 consecutive days), followed by concomitant capecitabine (2,000 mg/m2 per day for 2 weeks followed by a 1-week break) and sunitinib (37.5 mg daily, continuously). The primary end- point was progression-free survival (PFS).Results. Of 25 planned patientsthat would be required to detect a 4-month improvement (from 5 to 9 months) in median PFS with 80% power, 12 were enrolled, and the study was then closed forslow accrual. Median PFS was 4.7 months, and median overall survival was 10 months. In the CNS, 25% had progressive disease, and 83% experienced extra-CNS progression. The most common side effects were fatigue and nausea.Conclusion. In 12 evaluable patients studied, concurrent capecitabine and whole-brain radiation followed by capecita- bine and sunitinib did not extend PFS over historical rates and was associated with significant toxicity. Our study was small and closed due to slow accrual.

AB - Background. Brain metastasis from breast cancer presents a significant threat to women’s health and quality of life. Capecitabine and sunitinib have shown some activity in this setting; there- fore, we conducted a single-arm phase II trial with these agents. Methods. Patients with breast cancer and central nervous system (CNS) metastases received whole-brain radiotherapy concurrently with capecitabine (1,000 mg/m2 per day for 14 consecutive days), followed by concomitant capecitabine (2,000 mg/m2 per day for 2 weeks followed by a 1-week break) and sunitinib (37.5 mg daily, continuously). The primary end- point was progression-free survival (PFS).Results. Of 25 planned patientsthat would be required to detect a 4-month improvement (from 5 to 9 months) in median PFS with 80% power, 12 were enrolled, and the study was then closed forslow accrual. Median PFS was 4.7 months, and median overall survival was 10 months. In the CNS, 25% had progressive disease, and 83% experienced extra-CNS progression. The most common side effects were fatigue and nausea.Conclusion. In 12 evaluable patients studied, concurrent capecitabine and whole-brain radiation followed by capecita- bine and sunitinib did not extend PFS over historical rates and was associated with significant toxicity. Our study was small and closed due to slow accrual.

UR - http://www.scopus.com/inward/record.url?scp=84921318186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921318186&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2014-0278

DO - 10.1634/theoncologist.2014-0278

M3 - Article

C2 - 25378456

AN - SCOPUS:84921318186

VL - 20

SP - 13

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 1

ER -